Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Belatacept is the first approved costimulatory blockade agent for transplant immunosuppression.
• It demonstrates superior long-term renal allograft and patient survival compared to calcineurin inhibitor (CNI)-based regimens.
• Clinical adoption is limited by concerns of acute cellular rejection (ACR) and administration barriers.

Purpose of the Study:

• To review the clinical development and approval of belatacept.
• To examine novel CNI-free regimens and strategies to mitigate ACR risk.
• To explore future avenues for increasing belatacept adoption and expanding its indications.

Main Methods:

• Review of clinical trial data, including the BENEFIT and BENEFIT-EXT trials.
• Analysis of clinical experience with belatacept-based immunosuppression, including CNI-sparing approaches.
• Discussion of logistical improvements and expanded indications for belatacept.

Main Results:

• Belatacept provides long-term survival benefits in renal transplantation.
• Concerns regarding early ACR and administration logistics have hindered widespread use.
• Strategies like CNI-tapering and exploring subcutaneous administration show promise.

Conclusions:

• Belatacept offers significant long-term benefits but requires strategies to overcome adoption barriers.
• Optimizing administration and expanding indications could increase its clinical utility.
• Future research into novel immunosuppressants may further enhance costimulation blockade use.